Overall survival (OS) of acute erythroid leukemia (AEL) patients by clinical subgroups. The therapy-related AEL patients (T-AEL) had a median OS of 4.5 months, inferior to that of de novo AEL patients (N-AEL; median OS, 11 months; P < .001) and patients with AEL after an antecedent myelodysplastic syndrome or chronic cytopenia (MDS-AEL; median OS, 17 months; P = .001). There was no difference in OS between the N-AEL and MDS-AEL patients (P = .99).